Maze Therapeutics (MAZE) Total Liabilities (2024 - 2026)
Maze Therapeutics (MAZE) posted Total Liabilities of $78.0 million for Q1 2026, up 85.03% sequentially from $42.2 million in Q4 2025, and up 91.33% YoY from $40.8 million in Q1 2025.
Maze Therapeutics (MAZE) Total Liabilities (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Total Liabilities for 3 years, with the latest figure at $78.0 million in Q1 2026.
- Quarterly Total Liabilities rose 91.33% year-over-year to $78.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.0 million (up 91.33% YoY) and the FY2025 annual result came in at $42.2 million, down 3.38% from the prior year.
- Total Liabilities climbed to $78.0 million in Q1 2026 per MAZE's latest filing, from $42.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $78.0 million in Q1 2026 and troughed at $40.8 million in Q1 2025.
- A 3-year average of $48.1 million and a median of $42.4 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities fell 3.38% in 2025, then jumped 91.33% in 2026.
- Over 3 years, Total Liabilities stood at $43.6 million in 2024, then slipped by 3.38% to $42.2 million in 2025, then surged by 85.03% to $78.0 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $78.0 million, $42.2 million, and $42.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 78.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.50 Mn |
| Mar 31, 2026 | 78.01 Mn |
| Dec 31, 2025 | 42.16 Mn |
| Sep 30, 2025 | 42.62 Mn |
| Jun 30, 2025 | 41.28 Mn |
| Mar 31, 2025 | 40.77 Mn |
| Dec 31, 2024 | 43.64 Mn |